VolitionRx Limited (VNRX)
$0.77
-0.01 (-0.77%)
Rating:
Recommendation:
Buy
| Symbol | VNRX |
|---|---|
| Price | $0.77 |
| Beta | 1.680 |
| Volume Avg. | 0.18M |
| Market Cap | 60.588M |
| Shares () | - |
| 52 Week Range | 0.58-2.74 |
| 1y Target Est | - |
| DCF Unlevered | VNRX DCF -> | |
|---|---|---|
| DCF Levered | VNRX LDCF -> | |
| ROE | 12205.15% | Strong Buy |
| ROA | -187.70% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | -210.73% | Sell |
| P/E | -1.48 | Sell |
| P/B | -29.47 | Strong Sell |
Latest VNRX news
About
Download (Excel)Mr. Cameron Reynolds MBA
Healthcare
Diagnostics & Research
American Stock Exchange
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.